Posted by Michael Wonder on 13 Jun 2017
Amgen’s myeloma treatment Kyprolis gains NICE approval
13 June 2017 - NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.
As is now virtually standard, the drug was approved with a patient access scheme, the confidential discounting scheme operating by NICE.
This means Kyprolis (carfilzomib) in combination with dexamethasone is now recommended by NICE as an option for treating adults with relapsed multiple myeloma who have received one prior therapy that does not include Velcade (bortezomib).
